NeuraxisNRXS
NRXS
About: Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
Employees: 19
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
156% more capital invested
Capital invested by funds: $308K [Q2] → $790K (+$481K) [Q3]
2.07% more ownership
Funds ownership: 1.67% [Q2] → 3.73% (+2.07%) [Q3]
10% less funds holding
Funds holding: 10 [Q2] → 9 (-1) [Q3]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Research analyst outlook
We haven’t received any recent analyst ratings for NRXS.
Financial journalist opinion
Based on 4 articles about NRXS published over the past 30 days
Neutral
GlobeNewsWire
6 hours ago
UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States
CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), with a prominent insurer, with approximately 5.1 million members across 13 states.
Neutral
GlobeNewsWire
11 hours ago
NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States
CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), with Molina Healthcare. Molina, with over 40 years in operation, has approximately 5.1 million members across 13 states.
Neutral
GlobeNewsWire
1 week ago
NeurAxis Inc. Issues Letter to Shareholders
CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that CEO Brian Carrico has published a letter to shareholders highlighting the Company's achievements in 2024 and vision for 2025.
Neutral
GlobeNewsWire
2 weeks ago
NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
CARMEL, Ind., Jan. 06, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that CEO Brian Carrico will participate in a webcasted company presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.
Neutral
Seeking Alpha
2 months ago
NeurAxis, Inc (NRXS) Q3 2024 Earnings Call Transcript
NeurAxis, Inc (NYSE:NRXS ) Q3 2024 Results Conference Call November 12, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Operator Good day, and thank you for standing by. Welcome to the NeurAxis's Third Quarter 2024 Financial Results Conference Call.
Positive
Zacks Investment Research
2 months ago
NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage
NRXS reports strong third-quarter results with rising revenues, reduced losses and expanded insurance coverage, driving its stock to outperform the market.
Neutral
GlobeNewsWire
2 months ago
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues
Conference call will be held today, Tuesday, November 12 at 9:00 am ET Conference call will be held today, Tuesday, November 12 at 9:00 am ET
Neutral
GlobeNewsWire
3 months ago
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation
CARMEL, Ind., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, announced that the American Medical Association (AMA) has established a new Current Procedural Terminology (CPT) Category I code for Percutaneous Electrical Nerve Field Stimulation (PENFS) procedures effective January 1, 2026.
Neutral
Zacks Investment Research
3 months ago
Zacks Initiates Coverage of NeurAxis With Neutral Recommendation
Discover why Zacks rates NeurAxis as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore NRXS' promising growth prospects and financial health amid market challenges.
Neutral
GlobeNewsWire
4 months ago
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
CARMEL, Ind., Sept. 19, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024.
Charts implemented using Lightweight Charts™